U.S. FDA Grants Fast Track designation for HLX-1502 in Neurofibromatosis Type 1 (NF1) Treatment

Why Fast Track designation Matters The Fast Track designation is awarded by the FDA to facilitate the development and review of drugs that treat serious conditions and fill unmet medical needs. For our team, it means increased interaction with FDA experts throughout the development process, allowing us to gain early feedback on crucial steps, such … Continued The post U.S. FDA Grants Fast Track designation for HLX-1502 in Neurofibromatosis Type 1 (NF1) Treatment appeared first on Healx .